Literature DB >> 21955235

Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art.

Anant R C Patel1, John R Hurst.   

Abstract

Extrapulmonary comorbidities are common and significant in chronic obstructive pulmonary disease (COPD), often contributing to symptoms, exacerbations, hospital admissions and mortality. Cardiovascular, musculoskeletal and psychological conditions are among the most prevalent and important of these. In particular, ischemic heart disease is a leading cause of death in the COPD population as a whole. Here, we provide a state-of-the-art summary of key comorbidities observed in COPD patients in terms of their prevalence, impact, pathophysiology and prognosis. In addition, we review clinical, diagnostic and management strategies that may differ in COPD patients from the rest of the population.

Entities:  

Mesh:

Year:  2011        PMID: 21955235     DOI: 10.1586/ers.11.62

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  55 in total

1.  Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.

Authors:  Salim Merali; Carlos A Barrero; Russell P Bowler; Diane Er Chen; Gerard Criner; Alan Braverman; Samuel Litwin; Anthony Yeung; Steven G Kelsen
Journal:  COPD       Date:  2013-10-10       Impact factor: 2.409

2.  The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease.

Authors:  Bram van den Borst; Harry R Gosker; Annemarie Koster; Binbing Yu; Stephen B Kritchevsky; Yongmei Liu; Bernd Meibohm; Thomas B Rice; Michael Shlipak; Sachin Yende; Tamara B Harris; Annemie M W J Schols
Journal:  Am J Clin Nutr       Date:  2012-07-18       Impact factor: 7.045

3.  Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011.

Authors:  Abdulbaset Kamour; Mannino David; Sarojini Kanotra
Journal:  Chronic Obstr Pulm Dis       Date:  2015-10-15

4.  Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation.

Authors:  C van de Bool; C Mattijssen-Verdonschot; P P M J van Melick; M A Spruit; F M E Franssen; E F M Wouters; A M W J Schols; E P A Rutten
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

5.  Nutrition impact symptoms and body composition in patients with COPD.

Authors:  J Nordén; A M Grönberg; I Bosaeus; H Bertéus Forslund; L Hulthén; E Rothenberg; J Karlsson; O Wallengren; F Slinde
Journal:  Eur J Clin Nutr       Date:  2014-05-07       Impact factor: 4.016

Review 6.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

7.  Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.

Authors:  Fahrettin Talay; Mehmet Tosun; Zehra Asuk Yaşar; Özlem Kar Kurt; Aysel Karği; Serkan Öztürk; Mehmet Fatih Özlü; Aytekin Alçelik
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

8.  Population-based burden of COPD-related visits in the ED: return ED visits, hospital admissions, and comorbidity risks.

Authors:  Karin B Yeatts; Steven J Lippmann; Anna E Waller; Kristen Hassmiller Lich; Debbie Travers; Morris Weinberger; James F Donohue
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

9.  Effect of Virtual Reality-Based Rehabilitation on Physical Fitness in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Sebastian Rutkowski; Anna Rutkowska; Dariusz Jastrzębski; Henryk Racheniuk; Witold Pawełczyk; Jan Szczegielniak
Journal:  J Hum Kinet       Date:  2019-10-18       Impact factor: 2.193

Review 10.  Infection-Associated Mechanisms of Neuro-Inflammation and Neuro-Immune Crosstalk in Chronic Respiratory Diseases.

Authors:  Belinda Camp; Sabine Stegemann-Koniszewski; Jens Schreiber
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.